Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2013

View Archived Issues

Companies enter collaboration to develop Tregitope immune-modulating technology

Boston Scientific set to launch Promus Premier stent system in Europe

Japanese authorities remove condition for approval from Abraxane

Priority review granted to Bayer's NDA for radium-223

Amylin Pharmaceuticals patents new fusion proteins

GlaxoSmithKline presents novel TRPV4 antagonists

GlaxoSmithKline discloses novel tyrosine-protein kinase inhibitors

AstraZeneca synthesizes new inhibitors of mutated forms of EGFR

Pfizer designs new glucagon receptor antagonists

Xenetic Biosciences signs research agreement

ALX-0061 demonstrates good efficacy and safety in RA patients

Agilent Technologies and Sera Prognostics form partnership

Dako and Pfizer to collaborate on companion diagnostics

Peregrine Pharmaceuticals reports results from phase II bavituximab trial

Xencor begins phase Ib/IIa trial of XmAb-5871

GGF2 enhances post-stroke recovery of sensorimotor functions in vivo

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Phase III Fibrocaps trial achieves safety milestone

Phase III study finds no benefit for DP-b99 in acute ischemic stroke

Lundbeck reflects on highlights of 2012

Novo Nordisk gains price approval in Japan for once-daily basal insulin

EMA grants orphan designation to BHR Pharma's investigational agent for traumatic brain injury

Photoimmunotherapy enhances accumulation of nanosized chemotherapy in tumors

Lentigen obtains FDA orphan designation for novel gene therapy for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.